FDA Adverse Event Malfunction Summary report: N

COAGUCHEK ® XS SYSTEM

MDR report key: 7966100 · Received October 15, 2018

Report

Report Number
1823260-2018-03676
Event Type
Malfunction
Date Received
October 15, 2018
Date of Event
September 25, 2018
Report Date
January 16, 2019
Manufacturer
ROCHE DIAGNOSTICS
Product Code
GJS
PMA / PMN Number
K062925
Removal / Correction Number
NA
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
AS
Reporter Occupation
OTHER HEALTH CARE PROFESSIONAL

Narratives

Additional Manufacturer Narrative · 0

THE CUSTOMER DID NOT RETURN ANY MATERIALS FOR INVESTIGATION. WITHOUT THESE MATERIALS TO INVESTIGATE, A SPECIFIC ROOT CAUSE COULD NOT BE DETERMINED. RELEVANT RETENTION TEST STRIPS (LOT 244033) WERE TESTED IN COMPARISON WITH THE MASTER LOT COAGUCHEK XS PT. FOR THIS PURPOSE TWO HUMAN BLOOD SAMPLES FROM MARCUMAR DONORS AND TWO INTERNAL REFERENCE METERS WERE USED. RETENTION SAMPLES WERE ACCEPTABLE. NO ERROR MESSAGES OCCURRED. RETENTION MATERIAL COMPLIES WITH THE SPECIFICATION.

Additional Manufacturer Narrative · 1

THIS EVENT OCCURRED IN (B)(6).

Description of Event or Problem · 1

THE CUSTOMER STATED THAT THEY RECEIVED AN ERRONEOUS RESULT FOR ONE PATIENT TESTED WITH COAGUCHEK XS PRO METER SERIAL NUMBER (B)(4). THE CUSTOMER NOTED THAT THEY HAD ISSUES WITH RESULTS FROM OTHER PATIENTS, BUT PROVIDED NO DETAILS. A SAMPLE FROM THE PATIENT WAS TESTED ON THE METER, RESULTING AS 3.9 INR. ON THE SAME DAY AT AN UNKNOWN TIME, A SAMPLE FROM THE PATIENT WAS TESTED AT A LABORATORY USING AN UNKNOWN METHOD, RESULTING AS 2.8 INR. NO ADVERSE EVENTS WERE ALLEGED TO HAVE OCCURRED WITH THE PATIENT. THE PATIENT'S THERAPEUTIC RANGE IS 2 - 3 INR. THE PATIENT'S TESTING FREQUENCY IS ONCE PER MONTH. THE PATIENT'S WARFARIN DOSE HAS BEEN CONSTANT. THE CUSTOMER'S PRODUCT WAS REQUESTED FOR INVESTIGATION.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
808118 COAGUCHEK ® XS SYSTEM PROTHROMBIN TIME TEST STRIPS GJS ROCHE DIAGNOSTICS NA 24403317

Patients

Seq Age Sex Outcome Treatment
1 WARFARIN